FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence

Ana Blanca, Maria J. Requena, Jose Alvarez, Liang Cheng, Rodolfo Montironi, Maria R. Raspollini, Carlos Reymundo, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: To assess the diagnostic performance of FGFR3 and Cyclin D3 urinary protein levels in detecting bladder cancer recurrence. Patients & methods: Urine of 321 patients in follow-up for bladder cancer and 150 non-neoplastic urine controls was included. Cytology, cystoscopy and FGFR3 and Cyclin D3 expression by western blot were performed. Results: One hundred ten (34.3%) patients had evidence of tumor recurrence. The sensitivity and specificity of cytology/cystoscopy was 80 and 84%, and for FGFR3/Cyclin D3 was of 73 and 90%. Conclusion: Combined urinary FGFR3/Cyclin D3 expression shows improved detection rates for bladder cancer recurrence with high specificity and sensitivity, and within the same range of detection shown by cystoscopy, therefore supporting its potential use as noninvasive diagnostic biomarker for bladder cancer recurrence.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalBiomarkers in Medicine
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Cyclin D3
Biomarkers
Urinary Bladder Neoplasms
Cystoscopy
Urine
Cytology
Recurrence
Cell Biology
Sensitivity and Specificity
Tumors
Western Blotting
Neoplasms
Proteins

Keywords

  • bladder cancer
  • cyclin D3
  • diagnosis
  • FGFR3
  • urine
  • western blot

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

Blanca, A., Requena, M. J., Alvarez, J., Cheng, L., Montironi, R., Raspollini, M. R., ... Lopez-Beltran, A. (2016). FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. Biomarkers in Medicine, 10(3), 243-253. https://doi.org/10.2217/bmm.15.120

FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. / Blanca, Ana; Requena, Maria J.; Alvarez, Jose; Cheng, Liang; Montironi, Rodolfo; Raspollini, Maria R.; Reymundo, Carlos; Lopez-Beltran, Antonio.

In: Biomarkers in Medicine, Vol. 10, No. 3, 01.03.2016, p. 243-253.

Research output: Contribution to journalArticle

Blanca, A, Requena, MJ, Alvarez, J, Cheng, L, Montironi, R, Raspollini, MR, Reymundo, C & Lopez-Beltran, A 2016, 'FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence', Biomarkers in Medicine, vol. 10, no. 3, pp. 243-253. https://doi.org/10.2217/bmm.15.120
Blanca A, Requena MJ, Alvarez J, Cheng L, Montironi R, Raspollini MR et al. FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. Biomarkers in Medicine. 2016 Mar 1;10(3):243-253. https://doi.org/10.2217/bmm.15.120
Blanca, Ana ; Requena, Maria J. ; Alvarez, Jose ; Cheng, Liang ; Montironi, Rodolfo ; Raspollini, Maria R. ; Reymundo, Carlos ; Lopez-Beltran, Antonio. / FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. In: Biomarkers in Medicine. 2016 ; Vol. 10, No. 3. pp. 243-253.
@article{cab85b8d995f43cb8e6824fd09e9bf2d,
title = "FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence",
abstract = "Aim: To assess the diagnostic performance of FGFR3 and Cyclin D3 urinary protein levels in detecting bladder cancer recurrence. Patients & methods: Urine of 321 patients in follow-up for bladder cancer and 150 non-neoplastic urine controls was included. Cytology, cystoscopy and FGFR3 and Cyclin D3 expression by western blot were performed. Results: One hundred ten (34.3{\%}) patients had evidence of tumor recurrence. The sensitivity and specificity of cytology/cystoscopy was 80 and 84{\%}, and for FGFR3/Cyclin D3 was of 73 and 90{\%}. Conclusion: Combined urinary FGFR3/Cyclin D3 expression shows improved detection rates for bladder cancer recurrence with high specificity and sensitivity, and within the same range of detection shown by cystoscopy, therefore supporting its potential use as noninvasive diagnostic biomarker for bladder cancer recurrence.",
keywords = "bladder cancer, cyclin D3, diagnosis, FGFR3, urine, western blot",
author = "Ana Blanca and Requena, {Maria J.} and Jose Alvarez and Liang Cheng and Rodolfo Montironi and Raspollini, {Maria R.} and Carlos Reymundo and Antonio Lopez-Beltran",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/bmm.15.120",
language = "English (US)",
volume = "10",
pages = "243--253",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence

AU - Blanca, Ana

AU - Requena, Maria J.

AU - Alvarez, Jose

AU - Cheng, Liang

AU - Montironi, Rodolfo

AU - Raspollini, Maria R.

AU - Reymundo, Carlos

AU - Lopez-Beltran, Antonio

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim: To assess the diagnostic performance of FGFR3 and Cyclin D3 urinary protein levels in detecting bladder cancer recurrence. Patients & methods: Urine of 321 patients in follow-up for bladder cancer and 150 non-neoplastic urine controls was included. Cytology, cystoscopy and FGFR3 and Cyclin D3 expression by western blot were performed. Results: One hundred ten (34.3%) patients had evidence of tumor recurrence. The sensitivity and specificity of cytology/cystoscopy was 80 and 84%, and for FGFR3/Cyclin D3 was of 73 and 90%. Conclusion: Combined urinary FGFR3/Cyclin D3 expression shows improved detection rates for bladder cancer recurrence with high specificity and sensitivity, and within the same range of detection shown by cystoscopy, therefore supporting its potential use as noninvasive diagnostic biomarker for bladder cancer recurrence.

AB - Aim: To assess the diagnostic performance of FGFR3 and Cyclin D3 urinary protein levels in detecting bladder cancer recurrence. Patients & methods: Urine of 321 patients in follow-up for bladder cancer and 150 non-neoplastic urine controls was included. Cytology, cystoscopy and FGFR3 and Cyclin D3 expression by western blot were performed. Results: One hundred ten (34.3%) patients had evidence of tumor recurrence. The sensitivity and specificity of cytology/cystoscopy was 80 and 84%, and for FGFR3/Cyclin D3 was of 73 and 90%. Conclusion: Combined urinary FGFR3/Cyclin D3 expression shows improved detection rates for bladder cancer recurrence with high specificity and sensitivity, and within the same range of detection shown by cystoscopy, therefore supporting its potential use as noninvasive diagnostic biomarker for bladder cancer recurrence.

KW - bladder cancer

KW - cyclin D3

KW - diagnosis

KW - FGFR3

KW - urine

KW - western blot

UR - http://www.scopus.com/inward/record.url?scp=84959478581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959478581&partnerID=8YFLogxK

U2 - 10.2217/bmm.15.120

DO - 10.2217/bmm.15.120

M3 - Article

C2 - 26861974

AN - SCOPUS:84959478581

VL - 10

SP - 243

EP - 253

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 3

ER -